WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H524908
CAS#: 162712-35-8
Description: CVT-2513 is a ranolazine metabolites with anti-myocardial ischemia activity.
Hodoodo Cat#: H524908
Name: CVT-2513
CAS#: 162712-35-8
Chemical Formula: C14H22N2O3
Exact Mass: 266.16
Molecular Weight: 266.340
Elemental Analysis: C, 63.13; H, 8.33; N, 10.52; O, 18.02
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: CVT-2513; CVT 2513; CVT2513; RS-88681; RS88681; RS 88681.
IUPAC/Chemical Name: 1-Piperazineethanol, alpha-((2-methoxyphenoxy)methyl)-
InChi Key: HVPPJURUTODQOY-UHFFFAOYSA-N
InChi Code: InChI=1S/C14H22N2O3/c1-18-13-4-2-3-5-14(13)19-11-12(17)10-16-8-6-15-7-9-16/h2-5,12,15,17H,6-11H2,1H3
SMILES Code: COc1ccccc1OCC(CN2CCNCC2)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 266.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Yao Z, Gong S, Guan T, Li Y, Wu X, Sun H. Synthesis of ranolazine metabolites and their anti-myocardial ischemia activities. Chem Pharm Bull (Tokyo). 2009 Nov;57(11):1218-22. PubMed PMID: 19881270.
